Radiation

Momentus and Ascent Solar Technologies Partner to Bring Leading-Edge Solar Arrays to Market

Retrieved on: 
Wednesday, April 17, 2024
Titan, Radiation, ASTI, Partnership, Orbit, CIGS, Growth, SAN, Renewable energy

SAN JOSE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies, (Nasdaq: ASTI) (“Ascent”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.

Key Points: 
  • SAN JOSE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Momentus Inc. (NASDAQ: MNTS) ("Momentus") and Ascent Solar Technologies, (Nasdaq: ASTI) (“Ascent”) today announced a new partnership to jointly market leading-edge solar arrays utilizing the low-cost Tape Spring Solar Array (TASSA) being developed by Momentus and the high performance of Ascent’s flexible, lightweight photovoltaic modules.
  • Last year’s pathfinder TASSA demonstration validated solar blankets from Ascent, as a mass efficient and robust power generation solution.
  • Momentus plans to incorporate in TASSA new higher efficiency solar blankets from Ascent composed of space industry optimized Titan Modules, achieving even lower cost per kW of power.
  • “Ascent’s flexible, lightweight photovoltaic modules are ideal for the space environment,” said Paul Warley, CEO of Ascent Solar Technologies.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 17, 2024
FDA, Radiation, Prospectus, MCI, CMO, Sonder, Crohn's disease, News, Food, Annual report, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, Bank statement, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – CKPT

Retrieved on: 
Tuesday, April 16, 2024
FDA, Radiation, Action Replay, CMO, LLP, Person, Prior, News, Food, Complaint, Pomerantz, Biologics license application, District court, Patient, Court, Ext, Acquisition, CKPT, BLA, Checkpoint

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.

Key Points: 
  • NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer

Retrieved on: 
Tuesday, April 16, 2024
UCLA, FDA, Radiation, Cancer, CancerVax, Research, IND, Oncology, Barbara, Weapon, Ewing sarcoma, Protocol, Neoplasm, Immune system, Investigational New Drug, Vaccine

Ewing sarcoma is a rare and deadly bone and soft tissue cancer that primarily affects children and young adults.

Key Points: 
  • Ewing sarcoma is a rare and deadly bone and soft tissue cancer that primarily affects children and young adults.
  • The research program, funded by CancerVax, is led by a world class team of cancer researchers and oncologists who run the Ewing Sarcoma Program at the UCLA Jonsson Comprehensive Cancer Center.
  • This new type of cancer drug uses the body’s own immune system to fight cancer.
  • We believe this is a better way to treat cancer rather than the old methods of chemotherapy, radiation, and surgery.

CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action

Retrieved on: 
Monday, April 15, 2024
FDA, Radiation, CMO, LLP, News, Patient, Acquisition, CKPT, BLA, Checkpoint, SAN, Person, Pharmaceutical industry

SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.

Key Points: 
  • SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) securities between March 10, 2021 and December 15, 2023.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, April 15, 2024
FDA, Radiation, CMO, News, Complaint, Patient, Court, CKPT, BLA, CRL, Person

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points: 
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Checkpoint you have until June 4, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 13, 2024
FDA, Radiation, Prospectus, MCI, CMO, Crohn's disease, News, Food, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Retrieved on: 
Friday, April 12, 2024
FDA, Radiation, CMO, LLP, News, Advertising, Patient, Court, CKPT, BLA, CRL, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Checkpoint’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Radformation to Accelerate AI-Based Solutions with Limbus AI Acquisition

Retrieved on: 
Wednesday, May 1, 2024
Technology, Medical Devices, Hospitals, Health Technology, Software, Practice Management, Radiology, Health, Oncology, Artificial Intelligence, Radiation, Safety, Artificial intelligence, Workflow, Automation, Patient, Acquisition, Multimedia, Algorithm, Medical device

Radformation, Inc ., a leader in automation solutions for cancer care, announced today that it has acquired privately-held Limbus AI , a leading global provider of automated contouring software for radiation therapy.

Key Points: 
  • Radformation, Inc ., a leader in automation solutions for cancer care, announced today that it has acquired privately-held Limbus AI , a leading global provider of automated contouring software for radiation therapy.
  • This acquisition signifies Radformation’s commitment to driving innovation and expanding its AI-driven capabilities in cancer care.
  • “We share a similar vision to bring innovative software to patient care,” said Karl Otto, CEO of Limbus AI.
  • Radformation envisions a radiation oncology clinic where staff are equipped with solutions that supplement their expertise and automate tedious tasks, leading to better patient care everywhere.

Leading Radiation Oncologist Dr. Steven E. Finkelstein Joins Associated Medical Professionals of NY, an Affiliate of U.S. Urology Partners

Retrieved on: 
Tuesday, April 30, 2024
Medical Supplies, Biotechnology, Practice Management, Managed Care, Health, General Health, Radiology, Oncology, Medical Devices, Hospitals, Clinical Trials, Corporation, Micron Technology, University, Bangladesh Technical Education Board, Kidney, Hospital, Clinical research, Breast, National Cancer Institute, NMS, Literature, CARE, Prostate cancer, Radiation therapy, Patient, National Institutes of Health, Medicine, Physician, Lung, Radiation, Cancer, Medical imaging

Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals.

Key Points: 
  • Associated Medical Professionals of NY spans 18 locations in Central New York, including nine offices and nine hospitals.
  • Radiation Oncology is the region’s leading provider of comprehensive cancer care services, providing the most advanced, effective treatments available for urological and other types of cancers.
  • Steven Finkelstein’s extensive experience in radiation oncology care and his leadership in the medical field will be a tremendous asset to U.S. Urology Partners, Associated Medical Professionals of NY and most importantly to individuals receiving cancer care in the Central New York region.
  • I am excited to join the team of Associated Medical Professionals of NY and look forward to helping patients in the community.”